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Purpose: Vogt-Koyanagi-Harada (VKH) disease is a serious ocular inflammatory autoimmune insult directed against
antigens associated with melanocytes. The repertoire of killer cell immunoglobulin-like receptors (KIRs) is known to play
a significant role in the pathogenesis of various autoimmune disorders. Accordingly, we sought to determine the incidence
of KIR genes and KIR ligand (Human leukocytes antigen [HLA-C]) interaction in a cohort of Saudi VKH patients and to
compare the findings to normal controls.
Methods: A total of 30 patients with VKH and 125 control subjects were included. PCR using sequence-specific
oligonucleotide primers were employed to determine the genotype of the KIR genes and HLA-C alleles.
Results: The frequency of KIR2DS3 was significantly higher in the VKH patients than in the control group (p=0.048).
Two unique genotypes; VKHN*1 and VKHN*2 were observed in the VKH patients and not in normal controls. In addition,
the majority of the VKH patients (82%) in this study carry Bx genotypes that encode 2–5 activating KIR receptors. The
genotype Bx5 was found to be positively associated with the VKH patients (p=0.053). Significantly higher homozygosity
of HLA-C2 was observed in the VKH patients than in controls (p=0.005). Furthermore, HLA-C alleles-Cw*14 and Cw*17
were significantly prevalent in the VKH patients (p=0.037 and p=0.0001, respectively), whereas, Cw*15 significantly
increased in the control group (p=0.0205). Among potential KIR-HLA interactions, we observed KIR2DL2/2DL3+HLA-
C1 to be higher in the control subjects compared with the VKH patients (p=0.018).
Conclusions: Our findings indicated that KIR2DS3 and HLA-class I alleles (-Cw*14 and -Cw*17) may play a role in the
pathogenesis of VKH disease. Additionally, the predominance of KIR2DL2/2DL3+HLA-C1 in the controls may imply
that this KIR-ligand interaction could possibly play a role in the prevention of VKH disease, or could decrease its severity.
These observations may contribute to our understanding of the pathogenesis of VKH and other autoimmune diseases.
Vogt-Koyanagi-Harada (VKH) disease is a multisystem
disorder  characterized  by  granulomatous  panuvetitis  and
exudative  retinal  detachment  and  is  often  associated  with
neurologic  and  cutaneous  manifestations.  Ocular
inflammation may occur and the onset of VKH disease can be
associated  with  aseptic  meningitis,  as  well  as  with  the
subsequent development of vitiligo and hearing changes, as
part  of  the  putative  cell-mediated  autoimmune  response
affecting  melanocytes  [1,2].  Several  human  leukocyte
antigens (HLA) have been reported to be associated with VKH
disease, including HLA-DR4, HLA-DR53, and HLA-DQ4.
Strong association with the HLA-DRB1*0405 subtype has
been described in Japanese, Korean, and Saudi populations
[3–5], but not in the Mestizo population [6]. We recently
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reported a significant association of the HLA-DRB1*0405
allele with a Saudi VKH cohort. It is likely that other genetic
components of the immune system play a role in conferring
risk for VKH disease.
Several studies have shown the influence of killer cell
immunoglobulin-like receptors (KIRs), and KIR-ligand pairs,
in  terms  of  the  susceptibility  to  and  outcome  of  various
autoimmune  and  infectious  diseases,  such  as  AIDS  [7,8],
hepatitis  C  virus  infection  [9],  tuberculosis  [10],  leprosy
[11],  bird-shot  chorioretinopathy  [12],  idiopathic
brochiectasis [13], diabetes mellitus [14,15], Systemic lupus
erythromatous [16], Scleroderma [17], Sjogren’s syndrome
[18], and ankylosing spondilitis [19].
The polymorphic nature of KIR encodes receptors that
inhibit or activate natural killer (NK) cells and certain T-
lymphocyte subsets [20–22]. The inhibitory KIR (“iKIRs”)
2DL/3DL  recognizes  distinct  HLA  class  I  molecules  and
triggers signals to stop NK cell killing. Although the ligands
for  activating  KIRs  (“aKIRs”)  2DS/3DS  are  not  well
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3523acknowledged, certain aKIRs are predicted to bind to the same
HLA-class I ligands in a peptide-dependent manner as their
structurally related iKIRs [23]. In addition, the aKIRs interact
with the DAP-12 molecules, which modulate granulation and
cytokine production in NK cells [24]. Based on the genetic
content and the pattern of segregation at the population level,
KIR haplotypes are divided into two groups, A and B. Group
A haplotypes are defined by the presence of seven genes,
KIR2DL1, 2DL3, 2DL4, 3DL1, 3DL2, 3DL3, and 2DS4, and
two pseudo genes. However, group B haplotypes show high
genetic diversity and are characterized by the presence of
more than one aKIRs. KIR2DL4, 3DL2, 3DL3, and 3DP1 are
ubiquitously  present  in  all  individuals  and  are  termed
“framework” genes.
The activity of NK cells is controlled by the balance of
contra-regulatory  signals  derived  from  a  wide  variety  of
inhibitory and activating receptors [25].The balance in KIR
signaling is provided by the recognition of HLA molecules on
the surface of target cells, and some of these ligands are
already known. Dimorphism at residue 80 of the α1- helix in
HLA-C alleles defines two groups of KIR ligands, HLA-C1,
Cw*01, *03,*07,*08,*12,*13,*14, and *16- and -HLA-C2, -
Cw*02, *04, *05, *06,*15,*17, and *18, which are specific
for KIR2DL2/2DL3/2DS2 and KIR2DL1/2DS1, respectively
[26]. Genes encoding KIR and HLA are located on different
chromosomes  and  vary  in  both  number  and  type.  The
independent segregation of KIR and HLA genes results in
variable KIR-HLA combinations in individuals, which might
ultimately  determine  the  individual’s  immunity  and
susceptibility to disease [27]. Therefore, the objective of the
present study was to investigate the association of KIR genes
and potential KIR-ligand interactions in patients with VKH
disease in a cohort of the Saudi population.
METHODS
Patients and samples: Genomic DNA samples were collected
from 30 patients with VKH disease, as reported previously
[5], were stored at −80 °C, and were analyzed for the purpose
of the present study. A total of 125 controls were selected from
the earlier published data [28], which had a complete set of
data for KIR and HLA.
The VKH patients and controls were Saudi nationals from
different parts of the Kingdom of Saudi Arabia. The study was
reviewed and approved by the Institutional Review Board at
King Faisal Specialist Hospital and Research Centre, Riyadh,
Saudi Arabia. Written consent forms were duly signed by all
subjects included in the study.
Genotyping of KIR and HLA: DNA samples from the VKH
patients were typed for 14 KIR genes and two pseudo genes
using a single stranded polymorphism typing system by Dynal
KIR genotyping kit (Invitrogen Corp, Carlsbad, CA). HLA-
C typing was performed using a high-resolution sequence
based typing (SBT) kit (Excellerator HLA kit; Qiagen Inc.,
Valencia, CA), as previously described [28]. Genotyping tests
for  all  novel  genotypes  were  repeated  for  the  purpose  of
confirmation.
Data  analysis  and  statistical  methods:  The  phenotypic
frequency of each KIR was calculated as the percentage of
positive  numbers  among  all  individuals.  The  statistical
software package SAS, version 9.2 (SAS Institute Inc., Cary,
NC) was used for data analysis. Differences in the frequencies
of KIR and HLA-C genes between controls and the VKH
patients were tested by two-tailed Fisher’s exact probabilities,
and  p<0.05  was  considered  statistically  significant.  Odds
Ratios  (OD)  with  95%  Confidence  Intervals  (CI)  were
calculated for comparisons showing significant differences
between the patients and the control group.
RESULTS
A total of 30 patients with VKH were studied and compared
to 125 Saudi controls who had a complete set of KIR and
HLA data reported earlier [28].The constituents of the control
group were not related to the patients or to each other and were
Figure 1. The distribution of killer cell
immunoglobulin-like  receptor  (KIR)
gene frequencies in Saudi patients with
Vogt-Koyanagi-Harada (VKH) disease
and in control subjects. The frequency
of  each  gene  is  expressed  as  a
percentage and is defined as the number
of individuals possessing the genotype
(N+),  divided  by  the  total  number  of
individuals  studied  (n).  *KIR2DS3  is
significantly higher in the VKH patients
compared to the controls. The KIR data
for the Saudi controls was obtained from
our  previous  publication  [28].  The
framework  genes  (KIR3DL2,  3DL3,
2DL4,  and  3DP1)  were  invariably
present in all individuals.
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3524all of the same ethnic origin. All of the 16 KIR genes were
identified in our VKH patients and the controls, and the four
framework genes (KIR2DL4,3DL2,2DP1, and 3DL3) were
present in all the subjects tested. The frequencies of iKIR and
aKIR genes in the VKH patients and the controls are outlined
in Figure 1. The frequencies of individual KIR genes were
found to be similar in the controls and the VKH patients, with
the exception of KIR2DS3, which was significantly higher in
the VKH patients compared to the healthy controls (50% in
VKH and 34.4% in controls; p=0.048; OD=1.907; CI=0.85–
4.26). Furthermore, 19 [19] KIR genotypes that differed in
terms of their gene content were observed in 30 VKH patients.
We  observed  two  unique  KIR  profiles  (VKHN*1  and
VKHN*2) from two VKH patients that were not found among
any  of  the  Saudi  control  subjects  (Figure  2,  marked  by
asterisks). Even though the observed difference did not reach
statistical significance, the observation is important as it has
not been previously reported elsewhere. Nine [9] genotypes
were shared between the VKH patients and the Saudi controls.
The frequency of the AA1 genotype was observed to be higher
in the controls than in the VKH patients, with a gene frequency
of 26.4% and 16.7%, respectively. The ratio of the A:Bx
haplotype was found to be 0.33 and 0.20 for the controls and
the VKH patients, respectively, (data not shown), indicating
the predominance of B haplotype in the VKH patients. Among
all the genotypes, only Bx5 reached statistical significance in
the VKH patients (p=0.053; OD=2.41; CI=0.73–7.24).
The differences in the frequencies of HLA-C and KIR-
HLA-C complex between patients with VKH disease and the
control  group  were  statistically  significant  (Table  1).
Significant HLA-C2 homozygosity was measured in the VKH
patients (p=0.005; OD=3.23; CI=1.42–7.33). In contrast, the
controls were found to have higher HLA-C1 homozygosity
than the VKH patients (p=0.029; OD=0.13; CI=0.017–1.009).
Figure 2. Killer cell immunoglobulin-
like receptor (KIR) genotypes in Saudi
patients  with  Vogt-Koyanagi-Harada
(VKH) disease and in control subjects.
Data for the Saudi control individuals
was  previously  published  [28].  The
frequency of each genotype is expressed
as a percentage and is defined as the
number  of  individuals  possessing  the
genotype (+N), divided by the number
of individuals studied (n) in each group.
VKHN*1 and VKHN*2 are two unique
genotypes  and  are  marked  with  an
asterisk. **The frequency of the Bx5
genotype  was  measured  as  being
significantly higher in the VKH patients
compared  to  the  normal  controls.
(p=0.053; OD=2.41; CI=0.73–7.24).
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3525To explore KIR-HLA class I interactions, the presence of
KIR genes (KIR2DL1, 2DL2, 2DL3, 2DS1, and 2DS2) and
their specific ligands were screened in both the VKH patients
and  the  controls.  The  frequency  of  KIR2DL2/3-HLA-C1
interactions was significantly prevalent in the control subjects
(p=0.018; OD=0.36; CI=0.16–0.83) compared with the VKH
patients (Table 1). Other potential interactions between iKIRs/
aKIRs and HLA ligands were found to be similar between the
VKH  patients  and  the  controls  (Table  1).  When  the
frequencies of HLA-C alleles were compared, HLA-Cw *14
(C1 group) and -Cw*17 (C2 group) were observed to be
significantly higher in the VKH patients than in the controls
(p=0.037; OD=5.31; CI=4.21–6.69 and p<0.010; OD=21.88;
CI=4.59–104.29,  respectively)  (Table  2).  However,  HLA-
Cw*15 (C2 group) was significantly higher in the controls
than in the VKH patients (p=0.020; OD=0.308; CI=0.10–
0.89) as shown in Table 2.
DISCUSSION
KIRs are a relatively recent discovery; while the biologic
functions of iKIRs are well described, the function of aKIRs
is less clear [29]. Disease association studies have shown that
aKIR genotypes and KIR-HLA complexes are, in general,
associated with a higher risk of autoimmune diseases [27]. We
previously  reported  a  significant  association  of  HLA-
DRB1*0405 with the VKH patients [5]. Although the clinical
manifestations of VKH are well outlined [2], its exact etiology
remains to be elucidated. It is believed that T-lymphocyte-
mediated autoimmune processes are directed against an, as
yet, unidentified antigen or group of antigens associated with
melanocytes [1,4,5]. In this study, we found that the VKH
patients have a higher frequency of the activating KIR2DS3
gene  compared  with  healthy  controls.  Additionally,  our
results confirm the previous observations made by Levinson
et al. [30], who reported a predominance of activating KIR
genes  in  Mestizo  VKH  patients.  Although,  the  observed
TABLE 1. COMPARISON OF HLA-CLASS I (-CW) AND KIR - HLA-C COMPLEX IN A COHORT OF SAUDI PATIENTS WITH VKH DISEASE AND CONTROL SUBJECTS.
 
Controls (n=125) VKH patients (n=30)
   
HLA-C/KIR-HLA Complex (N+) %F (N+) %F p-value OD 95%(CI)
HLA-Cw*
HLA-C1/C1 26 20.8 1 3.3 0.0291 0.13 (0.017–1.009)
HLA-C1/C2 63 50.4 12 40    
HLA-C2/C2 36 28.8 17 56.7 0.0054 3.23 (1.42–7.33)
KIR-HLA(KIR ligand)
KIR2DL2/3-HLA-C1 88 70.4 14 46.7 0.0184 0.367 (0.163–0.830)
KIR2DL1-HLA-C2 97 77.6 28 93.3    
KIR2DS2-HLA-C1 52 41.6 9 30    
KIR2DS1-HLA-C2 32 25.6 8 26.7    
TABLE 2. FREQUENCY OF HLA-CW* ALLELES IN SAUDI PATIENTS WITH VKH DISEASE AND CONTROL SUBJECTS.
     
HLA-C alleles Alleles (n) % Alleles (n) % p value OD 95%(CI)
cw*01/C1 15 6 2 3.3    
cw*02/C2 8 3.2 2 3.3    
cw*03/C1 10 8 1 1.6    
cw*04/C2 26 10.4 6 10    
cw*05/C1 1 0.4 1 1.6    
cw*06/C2 52 20.8 19 31.6    
cw*07/C1 52 20.8 9 15    
cw*08/C1 10 4 1 1.6    
cw*12/C1 20 8 1 1.6    
cw*14//C1 0 0 2 3.3 0.037 5.3103(4.211–6.696)
cw*15/C2 47 18.8 4 6.7 0.0205 0.3085 (1.06–0.893)
cw*1507/C1 1 0.4 0 0    
cw*16/C1 4 1.6 0 0    
cw*1602/C2 2 0.8 2 3.3    
cw*17/C2 2 0.8 9 15 <0.0001 21.88 (4.59–104.29)
cw*18/C2 0 0 1 1.6    
Total no of alleles (n) 250   60      
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Controls (n=125) VKH patients (n=30)difference in their study is not statistically significant, it is in
keeping with the trend observed in other autoimmune diseases
[12]. Interestingly, the preponderance of aKIRs in the VKH
patients compared to normal controls suggests that T cell, T
cell subsets, and NK cells bearing KIRs might participate in
the pathology of the disease. In support of our findings, other
studies have demonstrated the association of aKIR genes with
a poor prognosis for patients with the Ebola virus infection
[31] and other ocular inflammatory disease, like bird shot
chorioretinopathy [12]. Moreover, we observed that group B
KIR haplotypes predominate in the VKH patients, compared
with  the  controls.  However,  only  the  difference  in  the
frequency  of  the  Bx5  genotype  reached  statistical
significance.  This  might  point  to  a  role  played  by  this
genotype in the predisposition or the immunopathology of
disease.  The  predominance  of  the  B  haplotype  in  VKH
patients was also found to be consistent with other published
studies [30]. Two unique genotypic profiles VKHN*1 and
VKHN*2 were only detected in the VKH patients and not in
the normal Saudi controls and the difference was not found to
be  statistically  significant,  as  only  one  individual  was
measured in each genotype. It is conceivable to postulate that
the presence of these two genotypes, alone or in combination
with others, has biologic relevance to the disease. Indeed,
more  investigations  are  required  to  prove  the  previous
hypothesis and to identify their exact role in VKH diseases.
It  is  recognized  that  the  function  of  KIR  is  highly
dependent on the HLA molecules expressed on the target
cells,  and  both  KIR  and  HLA  show  a  high  degree  of
polymorphism in the populations. Accordingly, we analyzed
the risk conferred by the potential interactions of KIR genes
with HLA-C in the VKH patients and the control subjects.
Only  KIR2DL2/3-HLA-C1  was  found  to  be  significantly
higher in our control population. This was indicative of the
inhibitory or protective role played by NK cells. Data from
genetic association studies suggest that the signals transduced
by aKIRs, upon binding to their putative HLA class I, may
serve  to  overcome  HLA  class  I-dependent  inhibition  and
trigger NK reactivity, leading to an autoimmune condition, as
in VKH disease. Although, the precise physiologic ligands for
aKIRs are not well defined, KIR tetramer-binding studies
imply that activating and inhibitory receptors recognize the
same set of HLA class I molecules, but differ in their binding
affinities. This allows fine tuning during cellular activation
[23]. There is considerable support for the notion that non-
HLA molecules may behave as ligands for aKIRs [25]. It is
plausible that KIR2DS3 acts by directly recognizing virally
encoded proteins, or by recognizing HLA-loaded viral peptide
complexes [25]. It is acknowledged that KIR- positive T-cells
expressing the adaptor molecule killer cell-activating receptor
associated  protein  (KARAP)/DAP-12,  can  be  stimulated
directly  with  KIR2DS3  to  release  cytokines  and  become
cytotoxic, without the need for conventional T-cell receptor
(TCR) recognition by antigenic peptides [24]. Both KIR and
HLA demonstrate a high degree of polymorphism in a given
population [20]. In this study, the HLA-Cw*15 allele was
more frequently observed in controls, which might point to
the role it plays in offering protection from VKH disease.
Alternatively, the strong association of the VKH disease with
HLA-Cw*14  and  -Cw*17*  alleles  may  suggest  that  the
aKIRs, upon binding to their putative HLA-class I ligands,
could overcome HLA class I-dependent inhibition and trigger
NK cell reactivity, leading to an autoimmune condition such
as VKH disease.
Finally, accumulating evidence indicates that aKIRs, and
their corresponding specific HLA-C ligands, might contribute
to the pathogenesis of VKH disease by modulating NK cells
and T cell functions.
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